This week on Contemporary OB/GYN®: Jan. 3 to Jan. 7
A look at what's coming to Contemporary OB/GYN® this week
FDA authorizes Pfizer, Merck COVID-19 antiviral pills
The moves bring two new weapons to the toolbox for physicians fighting the pandemic.
Top 3 challenges of 2022
Each year, the Medical Economics® team surveys their audience to find out what big challenges practitioners faced. By far, the top answer was “administrative burdens,” including staffing, prior authorizations and electronic health records (EHRs). Let's take a closer look at what these burdens entail to help physicians get ready for whatever challenges 2022 will bring.
Hair dyes, bleach, relaxers, and mousse associated with lower levels of sex steroid hormones
A new Rutgers study indicates a connection between specific personal care products and lower levels of sex steroid hormones, which have a critical role in maintaining pregnancy and fetal development.
Coming soon
Pap Talk: Season 4
With the new year, Contemporary OB/GYN® kicks off a new season of its Pap Talk podcast on Wednesday, Jan. 5.
Coming soon
Community births, and risks, increase with COVID-19 pandemic
New research in the American Journal of Obstetrics and Gynecology showed a rise in community births during the COVID-19 pandemic, as many women thought a hospital delivery to be more dangerous. The data told a different story.
Coming soon
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
